NasdaqGS:MRNA (Moderna, Inc.)
About MRNA
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Moderna, Inc. (NasdaqGS: MRNA) Latest News
Investing Articles
Is Moderna stock set for an explosive rise in 2023?
Growth Shares
Can Moderna stock triple my money this year?
Investing Articles
My 3 best stocks to buy in 2023
Investing Articles
Best British growth stocks to buy for December
Investing Articles
Is it time to buy Moderna shares?
Investing Articles
Is Moderna stock a buy?
Investing Articles
What is the Moderna share price really worth?
Investing Articles
I think these 2 S&P 500 stocks are severely overvalued
Investing Articles
Should I buy Moderna for my Stocks and Shares ISA?
Investing Articles
Moderna shares are beating the rest of the S&P 500. Am I buying?
Investing Articles
Can the Moderna share price keep rising?
Investing Articles
The Moderna share price has risen +400%: should I buy the stock now?
1❯